Low rates of adherence for tumor necrosis factor-α inhibitors in Crohn's disease and rheumatoid arthritis: Results of a systematic review

World Journal of Gastroenterology

Volumn 19, Issue 27, 2013, Pages 4344-4350

  Fidder, Herma H ^a   Singendonk, Maartje M J ^a   van der Have, Mike ^a   Oldenburg, Bas ^a   van Oijen, Martijn G H ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Adherence; Crohn's disease; Inhibitors; Rheumatoid arthritis; Systematic review; Tumor necrosis factor

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ARTICLE; CROHN DISEASE; HUMAN; MEDICATION COMPLIANCE; PATIENT COMPLIANCE; RHEUMATOID ARTHRITIS; SYSTEMATIC REVIEW (TOPIC);

EID: 84880400985     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i27.4344     Document Type: Article

References (31)

1. Furst DE, Keystone EC, Braun J, Breedveld FC, Burmester GR, De Benedetti F, Dörner T, Emery P, Fleischmann R, Gibofsky A, Kalden JR, Kavanaugh A, Kirkham B, Mease P, Sieper J, Singer NG, Smolen JS, Van Riel PL, Weisman MH, Winthrop K. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011. Ann Rheum Dis 2012; 71 SUPPL.2: i2-i45[PMID: 22460137 DOI: 10.1136/annrheumdis-2011-201036]
2. Ford AC, Sandborn WJ, Khan KJ, Hanauer SB, Talley NJ, Moayyedi P. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2011; 106: 644-659, quiz 660[PMID: 21407183 DOI: 10.1038/ajg.2011.73]
3. Ben-Horin S, Chowers Y. Review article: loss of response to anti-TNF treatments in Crohn's disease. Aliment Pharmacol Ther 2011; 33: 987-995[PMID: 21366636 DOI: 10.1111/ j.1365-2036.2011.04612.x]
4. Fernández-Nebro A, Irigoyen MV, Ureña I, Belmonte-López MA, Coret V, Jiménez-Núñez FG, Díaz-Cordovés G, López-Lasanta MA, Ponce A, Rodríguez-Pérez M, Calero E, González-Santos P. Effectiveness, predictive response factors, and safety of anti-tumor necrosis factor (TNF) therapies in anti-TNF-naive rheumatoid arthritis. J Rheumatol 2007; 34: 2334-2342[PMID: 17985409]
5. Jackson CA, Clatworthy J, Robinson A, Horne R. Factors associated with non-adherence to oral medication for inflammatory bowel disease: a systematic review. Am J Gastroenterol 2010; 105: 525-539[PMID: 19997092 DOI: 10.1038/ ajg.2009.685]
6. Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X. Interventions for enhancing medication adherence. Cochrane Database Syst Rev 2008; 16: CD000011[PMID: 18425859 DOI: 10.1002/14651858.CD000011.pub3]
7. Kane SV, Chao J, Mulani PM. Adherence to infliximab maintenance therapy and health care utilization and costs by Crohn's disease patients. Adv Ther 2009; 26: 936-946[PMID: 19838649 DOI: 10.1007/s12325-009-0069-7]
8. Juillerat P, Pittet V, Vader JP, Burnand B, Gonvers JJ, de Saussure P, Mottet C, Seibold F, Rogler G, Sagmeister M, Felley C, Michetti P, Froehlich F. Infliximab for Crohn's disease in the Swiss IBD Cohort Study: clinical management and appropriateness. Eur J Gastroenterol Hepatol 2010; 22: 1352-1357[PMID: 20964261]
9. Brocq O, Roux CH, Albert C, Breuil V, Aknouche N, Ruitord S, Mousnier A, Euller-Ziegler L. TNFalpha antagonist continuation rates in 442 patients with inflammatory joint disease. Joint Bone Spine 2007; 74: 148-154[PMID: 17368068]
10. Hetland ML, Lindegaard HM, Hansen A, Pødenphant J, Unkerskov J, Ringsdal VS, Østergaard M, Tarp U. Do changes in prescription practice in patients with rheumatoid arthritis treated with biological agents affect treatment response and adherence to therapy? Results from the nationwide Danish DANBIO Registry. Ann Rheum Dis 2008; 67: 1023-1026[PMID: 18272669 DOI: 10.1136/ard.2007.087262]
11. Hetland ML, Christensen IJ, Tarp U, Dreyer L, Hansen A, Hansen IT, Kollerup G, Linde L, Lindegaard HM, Poulsen UE, Schlemmer A, Jensen DV, Jensen S, Hostenkamp G, Østergaard M. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum 2010; 62: 22-32[PMID: 20039405 DOI: 10.1002/ art.27227]
12. Marchesoni A, Zaccara E, Gorla R, Bazzani C, Sarzi-Puttini P, Atzeni F, Caporali R, Bobbio-Pallavicini F, Favalli EG. TNFalpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice. Ann N Y Acad Sci 2009; 1173: 837-846[PMID: 19758236 DOI: 10.1111/j.1749-6632.2009.04621.x]
13. Wendling D, Materne GE, Michel F, Lohse A, Lehuede G, Toussirot E, Massol J, Woronoff-Lemsi MC. Infliximab continuation rates in patients with rheumatoid arthritis in everyday practice. Joint Bone Spine 2005; 72: 309-312[PMID: 16038842]
14. Grijalva CG, Chung CP, Arbogast PG, Stein CM, Mitchel EF, Griffin MR. Assessment of adherence to and persistence on disease-modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritis. Med Care 2007; 45: S66-S76[PMID: 17909386]
15. Grijalva CG, Kaltenbach L, Arbogast PG, Mitchel EF, Griffin MR. Adherence to disease-modifying antirheumatic drugs and the effects of exposure misclassification on the risk of hospital admission. Arthritis Care Res (Hoboken) 2010; 62: 730-734[PMID: 20191470 DOI: 10.1002/acr.20087]
16. Curkendall S, Patel V, Gleeson M, Campbell RS, Zagari M, Dubois R. Compliance with biologic therapies for rheumatoid arthritis: do patient out-of-pocket payments matter? Arthritis Rheum 2008; 59: 1519-1526[PMID: 18821651 DOI: 10.1002/art.24114]
17. Billioud V, Laharie D, Filippi J, Roblin X, Oussalah A, Chevaux JB, Hébuterne X, Bigard MA, Peyrin-Biroulet L. Adherence to adalimumab therapy in Crohn's disease: a French multicenter experience. Inflamm Bowel Dis 2011; 17: 152-159[PMID: 21061388 DOI: 10.1002/ibd.21491]
18. Kane S, Dixon L. Adherence rates with infliximab therapy in Crohn's disease. Aliment Pharmacol Ther 2006; 24: 1099-1103[PMID: 16984504]
19. Borah BJ, Huang X, Zarotsky V, Globe D. Trends in RA patients' adherence to subcutaneous anti-TNF therapies and costs. Curr Med Res Opin 2009; 25: 1365-1377[PMID: 19425902 DOI: 10.1185/03007990902896386]
20. Harley CR, Frytak JR, Tandon N. Treatment compliance and dosage administration among rheumatoid arthritis patients receiving infliximab, etanercept, or methotrexate. Am J Manag Care 2003; 9: S136-S143[PMID: 14577718]
21. Li P, Blum MA, Von Feldt J, Hennessy S, Doshi JA. Adher- ence, discontinuation, and switching of biologic therapies in medicaid enrollees with rheumatoid arthritis. Value Health 2010; 13: 805-812[PMID: 21054657 DOI: 10.1111/ j.1524-4733.2010.00764.x]
22. Bokemeyer B, Teml A, Roggel C, Hartmann P, Fischer C, Schaeffeler E, Schwab M. Adherence to thiopurine treatment in out-patients with Crohn's disease. Aliment Pharmacol Ther 2007; 26: 217-225[PMID: 17593067]
23. López San Román A, Bermejo F, Carrera E, Pérez-Abad M, Boixeda D. Adherence to treatment in inflammatory bowel disease. Rev Esp Enferm Dig 2005; 97: 249-257[PMID: 15982180]
24. Bernal I, Domènech E, Garcia-Planella E, Marín L, Mañosa M, Navarro M, Cabré E, Gassull MA. Medication-taking behavior in a cohort of patients with inflammatory bowel disease. Dig Dis Sci 2006; 51: 2165-2169[PMID: 17086434]
25. van den Bemt BJ, van Lankveld WG. How can we improve adherence to therapy by patients with rheumatoid arthritis? Nat Clin Pract Rheumatol 2007; 3: 681[PMID: 18037928]
26. Fidder H, Schnitzler F, Ferrante M, Noman M, Katsanos K, Segaert S, Henckaerts L, Van Assche G, Vermeire S, Rutgeerts P. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut 2009; 58: 501-508[PMID: 18832524 DOI: 10.1136/ gut.2008.163642]
27. Colombel JF, Loftus EV, Tremaine WJ, Egan LJ, Harmsen WS, Schleck CD, Zinsmeister AR, Sandborn WJ. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology 2004; 126: 19-31[PMID: 14699483]
28. Baert F, Noman M, Vermeire S, Van Assche G, D'Haens G, Carbonez A, Rutgeerts P. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003; 348: 601-608[PMID: 12584368]
29. Kane SV, Cohen RD, Aikens JE, Hanauer SB. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol 2001; 96: 2929-2933[PMID: 11693328]
30. Koncz T, Pentek M, Brodszky V, Ersek K, Orlewska E, Gulacsi L. Adherence to biologic DMARD therapies in rheumatoid arthritis. Expert Opin Biol Ther 2010; 10: 1367-1378[PMID: 20681888 DOI: 10.1517/14712598.2010.510508]
31. Mikkelsen TS, Wakefield MJ, Aken B, Amemiya CT, Chang JL, Duke S, Garber M, Gentles AJ, Goodstadt L, Heger A, Jurka J, Kamal M, Mauceli E, Searle SM, Sharpe T, Baker ML, Batzer MA, Benos PV, Belov K, Clamp M, Cook A, Cuff J, Das R, Davidow L, Deakin JE, Fazzari MJ, Glass JL, Grabherr M, Greally JM, Gu W, Hore TA, Huttley GA, Kleber M, Jirtle RL, Koina E, Lee JT, Mahony S, Marra MA, Miller RD, Nicholls RD, Oda M, Papenfuss AT, Parra ZE, Pollock DD, Ray DA, Schein JE, Speed TP, Thompson K, VandeBerg JL, Wade CM, Walker JA, Waters PD, Webber C, Weidman JR, Xie X, Zody MC, Graves JA, Ponting CP, Breen M, Samollow PB, Lander ES, Lindblad-Toh K. Genome of the marsupial Monodelphis domestica reveals innovation in non-coding sequences. Nature 2007; 447: 167-177[PMID: 17495919]